MX2019012158A - Tratamiento para el asma con anticuerpo anti-tslp. - Google Patents

Tratamiento para el asma con anticuerpo anti-tslp.

Info

Publication number
MX2019012158A
MX2019012158A MX2019012158A MX2019012158A MX2019012158A MX 2019012158 A MX2019012158 A MX 2019012158A MX 2019012158 A MX2019012158 A MX 2019012158A MX 2019012158 A MX2019012158 A MX 2019012158A MX 2019012158 A MX2019012158 A MX 2019012158A
Authority
MX
Mexico
Prior art keywords
asthma
treatment
tslp antibody
tslp
antibody
Prior art date
Application number
MX2019012158A
Other languages
English (en)
Spanish (es)
Inventor
R Parnes Jane
Griffiths Janet
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2019012158A publication Critical patent/MX2019012158A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019012158A 2017-04-12 2018-04-12 Tratamiento para el asma con anticuerpo anti-tslp. MX2019012158A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US201762553575P 2017-09-01 2017-09-01
US201762553477P 2017-09-01 2017-09-01
PCT/US2018/027271 WO2018191479A1 (en) 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody

Publications (1)

Publication Number Publication Date
MX2019012158A true MX2019012158A (es) 2019-12-16

Family

ID=62092313

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012158A MX2019012158A (es) 2017-04-12 2018-04-12 Tratamiento para el asma con anticuerpo anti-tslp.

Country Status (21)

Country Link
US (3) US10828365B2 (cg-RX-API-DMAC7.html)
EP (1) EP3609917A1 (cg-RX-API-DMAC7.html)
JP (4) JP7330896B2 (cg-RX-API-DMAC7.html)
KR (2) KR102666879B1 (cg-RX-API-DMAC7.html)
CN (1) CN110573525A (cg-RX-API-DMAC7.html)
AU (2) AU2018253118B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019021482A2 (cg-RX-API-DMAC7.html)
CA (1) CA3059364A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002897A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019011462A2 (cg-RX-API-DMAC7.html)
IL (1) IL269791B (cg-RX-API-DMAC7.html)
JO (1) JOP20190243A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019012158A (cg-RX-API-DMAC7.html)
MY (1) MY207509A (cg-RX-API-DMAC7.html)
PE (1) PE20200484A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502331A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201909322VA (cg-RX-API-DMAC7.html)
TN (1) TN2019000289A1 (cg-RX-API-DMAC7.html)
TW (2) TWI856945B (cg-RX-API-DMAC7.html)
UY (1) UY37676A (cg-RX-API-DMAC7.html)
WO (1) WO2018191479A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180042433A (ko) * 2015-09-09 2018-04-25 노파르티스 아게 흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
CN116751295A (zh) 2019-06-04 2023-09-15 江苏恒瑞医药股份有限公司 能结合胸腺基质淋巴细胞生成素的抗体及其应用
CA3147044A1 (en) * 2019-07-11 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
US12479912B2 (en) 2019-09-04 2025-11-25 Biosion Inc. Monoclonal antibodies which bind thymic stromal lymphopoietin (TSLP), encoding polynucleotides thereof and methods of use thereof to treat diseases
IL292437A (en) * 2019-10-28 2022-06-01 Medimmune Ltd Dry powder formulations of antibodies that bind thymic lymphopoietin (tslp) and methods of using them
CN114887053A (zh) * 2019-11-29 2022-08-12 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
US20220363781A1 (en) * 2019-12-13 2022-11-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4103605A1 (en) * 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
AU2021219839A1 (en) * 2020-02-13 2022-08-25 Amgen Inc. Formulations of human anti-TSLP antibodies and methods of treating inflammatory disease
JP2023513833A (ja) * 2020-02-18 2023-04-03 アムジェン インコーポレイテッド ヒト抗ｔｓｌｐ抗体の製剤及びそれを使用する方法
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
MX2023009971A (es) * 2021-03-03 2023-09-05 Chia Tai Tianqing Pharmaceutical Group Co Ltd Composicion farmaceutica que contiene anticuerpo anti-tslp.
KR20230172508A (ko) * 2021-04-19 2023-12-22 메디뮨 리미티드 안정성이 개선된 항-tslp fab
IL307439A (en) 2021-04-23 2023-12-01 Amgen Inc Different anti-TSLP antibodies
BR112023021867A2 (pt) 2021-04-23 2023-12-19 Amgen Inc Composições de anticorpo anti-tslp e seus usos
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN116217724B (zh) * 2021-12-02 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
AR133648A1 (es) * 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos anti-tslp y sus usos
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
EP3594356A1 (en) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
CA2924873A1 (en) * 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
SG10201913611QA (en) * 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
UY36578A (es) 2015-03-11 2016-09-30 Glaxosmithkline Ip Dev Ltd Proteínas de unión a tslp
UY36889A (es) * 2015-09-09 2017-04-28 Novartis Ag Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp

Also Published As

Publication number Publication date
JP7330896B2 (ja) 2023-08-22
BR112019021482A2 (pt) 2020-05-12
US20210052726A1 (en) 2021-02-25
SG11201909322VA (en) 2019-11-28
EP3609917A1 (en) 2020-02-19
JP2020516647A (ja) 2020-06-11
AU2018253118A1 (en) 2019-10-24
WO2018191479A1 (en) 2018-10-18
UY37676A (es) 2018-10-31
US20180296669A1 (en) 2018-10-18
TW202523688A (zh) 2025-06-16
TWI856945B (zh) 2024-10-01
IL269791B (en) 2022-07-01
MY207509A (en) 2025-02-28
US10828365B2 (en) 2020-11-10
CL2019002897A1 (es) 2020-03-06
TW201838652A (zh) 2018-11-01
AU2018253118B2 (en) 2025-04-10
CA3059364A1 (en) 2018-10-18
JP2023099233A (ja) 2023-07-11
KR20240070727A (ko) 2024-05-21
TN2019000289A1 (en) 2021-05-07
US20250032608A1 (en) 2025-01-30
JP2024150751A (ja) 2024-10-23
PH12019502331A1 (en) 2020-09-28
JP2025170430A (ja) 2025-11-18
IL269791A (en) 2019-11-28
CO2019011462A2 (es) 2019-10-31
AU2025204735A1 (en) 2025-07-17
KR20190140956A (ko) 2019-12-20
JOP20190243A1 (ar) 2019-10-13
KR102666879B1 (ko) 2024-05-23
PE20200484A1 (es) 2020-03-03
CN110573525A (zh) 2019-12-13

Similar Documents

Publication Publication Date Title
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
PH12018502113A1 (en) Chimeric receptors and methods of use thereof
JOP20200309A1 (ar) أجسام مضادة لـ il-11
MY210545A (en) Chimeric receptors to flt3 and methods of use thereof
PH12018500482A1 (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
MY205760A (en) Humanized antibodies against c-kit
BR112017008710A8 (pt) Composições e métodos para estimular a eficácia de imunoterapia celular adotiva
MY186352A (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2020010722A (es) Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.
MX2018012176A (es) Anticuerpos anti-factor bb del complemento y usos de estos.
NZ746609A (en) Ilt7 binding molecules and methods of using the same
ZA202205936B (en) Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2019013160A (es) Metodos de tratamiento selectivo del asma usando antagonistas de il-17.
MY192390A (en) Method for isolation of stem cells from bone marrow using subfractionation culturing method and proliferation thereof
MY201744A (en) Binding polypeptides and methods of making the same
MX2025008918A (es) Tratamiento para la rinosinusitis cronica con anticuerpos anti-tslp
MX2010007355A (es) Extracto de heteropterys brachiata, metodo de obtencion y uso para el tratamiento de ansiedad y depresion.